Table-IV.

Differences of characteristics between patients with and without BSIs during ECMO.

Characteristics	Without BSI (n = 50)	With BSI (n = 19)	P value
Demographic characteristics
Age, years	40 (18–77)	44 (21–67)	0.872
Female	19 (38.0)	7 (36.8)	0.929
Smoking history	12 (24.0)	6 (31.6)	0.522
Primary disease
Myocarditis	24 (48.0)	8 (42.1)	0.661
Respiratory failure	8 (16.0)	4 (21.1)	0.725
Coronary artery disease	13 (26.0)	6 (31.6)	0.643
Laboratory findings (Pre-ECMO)
White blood cell, 103/mm3	10.65 (2.20–36.7)	13.3 (5.2–37.7)	0.256
Hemoglobin, g/L	119.5 (61–176)	122 (70–174)	0.984
Platelets, 103/mm3	175.0 (33.0–396.0)	140 (11–857)	0.100
Lactate, mM	3.8 (1.0–20.0)	2.3 (1–19)	0.859
Total bilirubin, μM	14.0 (4.3–131.0)	20.1 (7.9–127)	0.079
Creatinine, μM	94.0 (44–466)	124 (55–297)	0.070
CRP, mg/dL	22.5 (1–176)	59 (1–194)	0.192
Pre-ECMO data
Pre-ECMO CPR	16 (32.0)	9 (47.5)	0.235
Veno-venous ECMO mode	8 (16.0)	4 (21.1)	0.725
Pre-ECMO SOFA score	8 (0–21)	11 (1-22)	0.008
Pre-ECMO ICU stay ≥ 1 day	12 (24.0)	6 (31.6)	0.522
Pre-ECMO ventilator duration ≥ 1 day	12 (24.0)	8 (42.1)	0.139
Pre-ECMO hospital stay ≥ 1 day	22 (44.0)	8 (42.1)	0.887
Pre-ECMO GCS	15 (3.0–15.0)	15 (3–15)	0.816
MRSA prophylactic regimen	13 (26.0)	10 (52.6)	0.036
During ECMO data
IABP during ECMO	13 (26.0)	8 (42.1)	0.194
CRRT during ECMO	18 (36.0)	12 (63.1)	0.042
Corticosteroid (methylprednisolone) before and during ECMO, mg	545 (0–3100)	560 (0–2860)	0.793
ECMO support duration, days	5.8 (2.3–30.3)	8.0 (3.6–26.0)	0.001
Before ECMO weaning data
ventilator duration before ECMO weaning, days	6 (0–32)	10 (3–26)	0.001
Prognosis
ECMO weaning (Success)	40 (80.0)	8 (42.1)	0.147
hospital stay, days	17.5 (2–42)	25 (10–39)	0.029
Survival-to-discharge rate	33 (66.0)	8 (42.1)	0.532